LPS-responsive
The present invention relates to a novel LPS-responsive and Beige-like Anchor gene (lrba), variants of the lrba gene, fragments of the lrba gene, and polypeptides encoded thereby. The subject invention also pertains to lrba interfering RNA, and uses thereof. In another aspect, the present invention also includes methods of inhibiting tumor growth in a patient by suppressing lrba function.
1. A method for inhibiting the growth of a tumor characterized by overexpression of the LPS-responsive CHS1/beige-like anchor gene (lrba) in a mammal, comprising directly administering an effective amount of an interfering RNA molecule to the tumor, wherein the interfering RNA is specific for lrba mRNA within the mammal and reduces lrba expression within the tumor, and wherein the interfering RNA inhibits growth of the tumor in the mammal.
2. The method according to claim 1 , wherein the interfering RNA is single-stranded RNA selected from the group consisting of SEQ ID NO. 177, SEQ ID NO. 178, SEQ ID NO. 179, and SEQ ID NO. 180.
3. The method according to claim 1 , wherein the interfering RNA is double-stranded RNA comprising SEQ ID NO. 177, SEQ ID NO. 178, SEQ ID NO. 179, or SEQ ID NO. 180.
4. The method of claim 1 , wherein the mammal is a human.
5. The method according to claim 1 , wherein the tumor is of a cancer type selected from the group consisting of breast, prostate, melanoma, cervical cancer, adenocarcinoma, colorectal cancer, and lung carcinoma.
6. The method according to claim 1 , wherein the tumor is of a cancer type selected from breast cancer or prostate cancer.
7. A method for inhibiting the growth of mammalian cancer cells characterized by overexpression of the LPS-responsive CHS1/beige-like anchor gene (lrba), comprising directly administering an effective amount of an interfering RNA molecule to the cancer cells in vitro or in vivo, wherein the interfering RNA is specific for lrba mRNA within the cancer cells and reduces lrba expression within the cancer cells, and wherein the interfering RNA inhibits growth of the cancer cells.
8. The method according to claim 7 , wherein the cancer cells are of a cancer type selected from the group consisting of breast, prostate, melanoma, cervical cancer, adenocarcinoma, colorectal cancer, and lung carcinoma.
9. The method according to claim 7 , wherein the cancer cells are of a cancer type selected from breast cancer or prostate cancer.
10. The method according to claim 7 , wherein the cancer cells are human cells.
11. The method according to claim 7 , wherein said administering is carried out in vivo.